{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:43:42Z","timestamp":1791031422247,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.2515\/therapie:2006040","type":"journal-article","created":{"date-parts":[[2007,4,19]],"date-time":"2007-04-19T14:59:53Z","timestamp":1176994793000},"page":"219-225","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacocin\u00e9tique des antifongiques en fonction du terrain"],"prefix":"10.1016","volume":"61","author":[{"given":"Michel","family":"Tod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2006040_bb0010","series-title":"AFAR (Annales Fran\u00e7aises d\u2019Anesth\u00e9sie et de R\u00e9animation) 2004 Num\u00e9ro sp\u00e9cial","article-title":"Conf\u00e9rence de consensus commune: prise en charge des candidoses et aspergilloses invasives de l\u2019adulte 2004","author":"Bretagne","year":"2004"},{"key":"10.2515\/therapie:2006040_bb0015","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1128\/AAC.44.4.938-942.2000","article-title":"In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model","volume":"44","author":"Andes","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.2515\/therapie:2006040_bb0025","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/AAC.1.6.476","article-title":"Pharmacological studies with 5-fluorocytosine","volume":"6","author":"Block","year":"1972","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000221923","article-title":"Metabolic studies with 5-fluocytosine-6-C-14 in mouse, rat, rabbit, dog and man","volume":"22","author":"Polak","year":"1976","journal-title":"Chemother"},{"issue":"5","key":"10.2515\/therapie:2006040_bb0035","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0022-3476(05)82674-5","article-title":"Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates","volume":"116","author":"Baley","year":"1990","journal-title":"JPediatr"},{"key":"10.2515\/therapie:2006040_bb0040","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00007691-200012000-00006","article-title":"Population pharmacokinetics of flucytosine","volume":"22","author":"Vermes","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie:2006040_bb0045","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.42.4.899","article-title":"Comparison of Fungizone, Amphotec, Ambisome and Abelcet for treatment of systemic murine cryptococcosis","volume":"42","author":"Clemons","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0050","first-page":"179","article-title":"Effect of tissue penetration on Ambisome efficacy","volume":"4","author":"Adler-Moore","year":"2003","journal-title":"Curr Opin Invest Drugs"},{"key":"10.2515\/therapie:2006040_bb0055","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1128\/AAC.45.3.922-926.2001","article-title":"Pharmacodynamics of amphotericin B in a neutropenic mouse disseminated candidiasis model","volume":"45","author":"Andes","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.2515\/therapie:2006040_bb0060","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1086\/314495","article-title":"Amphotericin B activation of human genes encoding for cytokines","volume":"178","author":"Rogers","year":"1998","journal-title":"J Infect Dis"},{"issue":"7286","key":"10.2515\/therapie:2006040_bb0065","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bmj.322.7286.579","article-title":"Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial","volume":"322","author":"Eriksson","year":"2001","journal-title":"BMJ"},{"key":"10.2515\/therapie:2006040_bb0070","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (Ambisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0075","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","article-title":"Plasma protein binding of amphotericin B and pharmacokinetics of bound vs unbound amphotericin B after administration of intravenous liposomal amphotericin B (Ambisome) and amphotericin B deoxycholate","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0080","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/clpt.1983.161","article-title":"Elimination of amphotericin B in impaired renal function","volume":"34","author":"Morgan","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie:2006040_bb0085","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.0306-5251.2001.01496.x","article-title":"Population pharmacokinetics of amphotericin B in children with malignant diseases","volume":"52","author":"Nath","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"suppl 2","key":"10.2515\/therapie:2006040_bb0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/clinids\/22.Supplement_2.S133","article-title":"Lipid formulations of amphotericin B: recent progress and future directions","volume":"22","author":"Hiemenz","year":"1996","journal-title":"Clin Inf Dis"},{"key":"10.2515\/therapie:2006040_bb0095","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1128\/AAC.42.9.2391","article-title":"Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (Ambisome) in neutropenic patients","volume":"42","author":"Walsh","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0100","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (Ambisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0105","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1128\/AAC.41.4.728","article-title":"Serum pharmacology of amphotericin B applied in lipid emulsions","volume":"41","author":"Heinemann","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 5","key":"10.2515\/therapie:2006040_bb0110","first-page":"S8","article-title":"Pharmacokinetics of liposomal amphotericin B (Ambisome) vs. other lipid-based formulations","volume":"14","author":"Heinemann","year":"1994","journal-title":"Bone Marrow Trans"},{"key":"10.2515\/therapie:2006040_bb0115","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1128\/AAC.41.10.2201","article-title":"Pharmacokinetic profile of Abelcet: combined experience from phase I and phase II studies","volume":"41","author":"Adedoyin","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0120","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1128\/AAC.44.10.2900-2902.2000","article-title":"A pharmacokinetic study of ABLC injection (Abelcet) in patients with definite or probable systemic fungal Infections","volume":"44","author":"Adedoyin","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0125","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1128\/AAC.41.9.1944","article-title":"Safety, tolerance and pharmacokinetics of ABLC in children with hepatosplenic candidiasis","volume":"41","author":"Walsh","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0130","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1128\/AAC.39.9.2042","article-title":"Population pharmacokinetics and renal function-sparing effect of ABCD in patients receiving bone marrow transplant","volume":"39","author":"Amantea","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0135","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jac\/dkg139","article-title":"Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration","volume":"51","author":"Bellmann","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.2515\/therapie:2006040_bb0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF02768745","article-title":"Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome)","volume":"26","author":"Weitkamp","year":"1998","journal-title":"Infection"},{"issue":"2","key":"10.2515\/therapie:2006040_bb0145","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00006454-199802000-00013","article-title":"Liposomal amphotericin B treatment for neonatal fungal infections","volume":"17","author":"Scarcella","year":"1998","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"10.2515\/therapie:2006040_bb0150","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/00006454-199908000-00010","article-title":"Amphotericin B lipid complex in pediatric patients with invasive fungal infections","volume":"18","author":"Walsh","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"10.2515\/therapie:2006040_bb0155","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1128\/AAC.47.4.1179-1186.2003","article-title":"In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0160","first-page":"149","article-title":"Pharmacokinetics of the azole antifungal agents: distinguishing differences","volume":"13","author":"Bergan","year":"1995","journal-title":"Antiinfect Drugs Chemother"},{"key":"10.2515\/therapie:2006040_bb0165","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2165\/00003088-199733010-00005","article-title":"Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses","volume":"33","author":"Debruyne","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.2515\/therapie:2006040_bb0170","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00001432-199712000-00007","article-title":"Potential new antifungal agents","volume":"10","author":"Groll","year":"1997","journal-title":"Curr Opin Infect Dis"},{"key":"10.2515\/therapie:2006040_bb0175","first-page":"387","article-title":"Itraconazole: pharmacokinetics and indications","volume":"24","author":"Negroni","year":"1993","journal-title":"Arch Med Res"},{"key":"10.2515\/therapie:2006040_bb0180","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/jac\/36.2.395","article-title":"Bioavailability of fluconazole administered via a feeding tube in intensive care patients","volume":"36","author":"Nicolau","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.2515\/therapie:2006040_bb0185","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/AAC.47.10.3375.2003","article-title":"Serum voriconazole levels following administration via percutaneous jejunostomy tube","volume":"47","author":"Martinez","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0190","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1128\/AAC.41.11.2554","article-title":"Pharmacokinetics of itraconazole (oral solution) in two groups of HIV-infected adults with oral candidiasis","volume":"41","author":"Reynes","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0195","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/jcp.50.6.477","article-title":"Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in AIDS patients with candidiosis","volume":"50","author":"Cartledge","year":"1997","journal-title":"J Clin Pathol"},{"key":"10.2515\/therapie:2006040_bb0200","doi-asserted-by":"crossref","first-page":"73141","DOI":"10.1124\/dmd.31.6.731","article-title":"The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog and human","volume":"31","author":"Roffey","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.2515\/therapie:2006040_bb0205","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1439-0507.1999.00518.x","article-title":"Itraconazole trough concentrations in antifongal prophylaxis with six different dosing regimens using oral solution or coated pellet capsules","volume":"42","author":"Glasmacher","year":"1999","journal-title":"Mycoses"},{"issue":"10","key":"10.2515\/therapie:2006040_bb0210","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1007\/s00134-003-1980-z","article-title":"Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration","volume":"29","author":"Yagasaki","year":"2003","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.2515\/therapie:2006040_bb0215","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00007691-200102000-00002","article-title":"Effective fluconazole therapy for liver transplant recipients during continuous hemodiafiltration","volume":"23","author":"Kishino","year":"2001","journal-title":"Ther Drug Monit"},{"issue":"10","key":"10.2515\/therapie:2006040_bb0220","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/AAC.32.10.1595","article-title":"Itraconazole pharmacokinetics in patients with renal dysfunction","volume":"32","author":"Boelaert","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.2515\/therapie:2006040_bb0225","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jac\/dkh310","article-title":"Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient","volume":"54","author":"Robatel","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.2515\/therapie:2006040_bb0230","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/jac\/35.5.641","article-title":"Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis","volume":"35","author":"Ruhnke","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.2515\/therapie:2006040_bb0235","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1128\/AAC.45.5.1561-1564.2001","article-title":"Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis","volume":"45","author":"Schmitt","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0240","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1128\/AAC.46.8.2554-2563.2002","article-title":"Safety, pharmacokinetics and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis","volume":"46","author":"Groll","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.2515\/therapie:2006040_bb0245","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0250","series-title":"In vivo pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis","author":"Wiederhold","year":"2003"},{"key":"10.2515\/therapie:2006040_bb0255","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.46.3.739-745.2002","article-title":"Single and multiple-dose pharmacokinetics of caspofungin in healthy men","volume":"46","author":"Stone","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006040_bb0260","series-title":"Pharmacokinetics of caspofungin in pediatric patients","author":"Walsh","year":"2002"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716303894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716303894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T07:00:01Z","timestamp":1554274801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716303894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0040595716303894"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2006040","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}